228 related articles for article (PubMed ID: 27371157)
41. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
[TBL] [Abstract][Full Text] [Related]
42. Prefrontal hyperactivation during a working memory task in early-onset schizophrenia spectrum disorders: an fMRI study.
Thormodsen R; Jensen J; Holmèn A; Juuhl-Langseth M; Emblem KE; Andreassen OA; Rund BR
Psychiatry Res; 2011 Dec; 194(3):257-262. PubMed ID: 22079661
[TBL] [Abstract][Full Text] [Related]
43. Nicotine effects on anterior cingulate cortex in schizophrenia and healthy smokers as revealed by EEG-informed fMRI.
Mobascher A; Warbrick T; Brinkmeyer J; Musso F; Stoecker T; Jon Shah N; Winterer G
Psychiatry Res; 2012 Nov; 204(2-3):168-77. PubMed ID: 23137805
[TBL] [Abstract][Full Text] [Related]
44. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
Olincy A; Stevens KE
Biochem Pharmacol; 2007 Oct; 74(8):1192-201. PubMed ID: 17714692
[TBL] [Abstract][Full Text] [Related]
45. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment.
Dunbar GC; Kuchibhatla RV; Lee G;
J Psychopharmacol; 2011 Aug; 25(8):1020-9. PubMed ID: 20542923
[TBL] [Abstract][Full Text] [Related]
46. Load-dependent hyperdeactivation of the default mode network in people with schizophrenia.
Hahn B; Harvey AN; Gold JM; Ross TJ; Stein EA
Schizophr Res; 2017 Jul; 185():190-196. PubMed ID: 28073606
[TBL] [Abstract][Full Text] [Related]
47. Functional and Neuroanatomic Specificity of Episodic Memory Dysfunction in Schizophrenia: A Functional Magnetic Resonance Imaging Study of the Relational and Item-Specific Encoding Task.
Ragland JD; Ranganath C; Harms MP; Barch DM; Gold JM; Layher E; Lesh TA; MacDonald AW; Niendam TA; Phillips J; Silverstein SM; Yonelinas AP; Carter CS
JAMA Psychiatry; 2015 Sep; 72(9):909-16. PubMed ID: 26200928
[TBL] [Abstract][Full Text] [Related]
48. The role of hippocampus dysfunction in deficient memory encoding and positive symptoms in schizophrenia.
Zierhut K; Bogerts B; Schott B; Fenker D; Walter M; Albrecht D; Steiner J; Schütze H; Northoff G; Düzel E; Schiltz K
Psychiatry Res; 2010 Sep; 183(3):187-94. PubMed ID: 20702070
[TBL] [Abstract][Full Text] [Related]
49. Prefrontal activity and impaired memory encoding strategies in schizophrenia.
Guimond S; Hawco C; Lepage M
J Psychiatr Res; 2017 Aug; 91():64-73. PubMed ID: 28325680
[TBL] [Abstract][Full Text] [Related]
50. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
[TBL] [Abstract][Full Text] [Related]
51. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
Prickaerts J; van Goethem NP; Chesworth R; Shapiro G; Boess FG; Methfessel C; Reneerkens OA; Flood DG; Hilt D; Gawryl M; Bertrand S; Bertrand D; König G
Neuropharmacology; 2012 Feb; 62(2):1099-110. PubMed ID: 22085888
[TBL] [Abstract][Full Text] [Related]
52. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory.
Gibbs SE; D'Esposito M
Psychopharmacology (Berl); 2005 Aug; 180(4):644-53. PubMed ID: 16001111
[TBL] [Abstract][Full Text] [Related]
53. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
Gilleen J; Farah Y; Davison C; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Reichenberg A; Williams SC; Mehta MA; Shergill SS
Psychopharmacology (Berl); 2021 May; 238(5):1279-1289. PubMed ID: 30536081
[TBL] [Abstract][Full Text] [Related]
54. Effects of nicotine and atomoxetine on brain function during response inhibition.
Kasparbauer AM; Petrovsky N; Schmidt PM; Trautner P; Weber B; Sträter B; Ettinger U
Eur Neuropsychopharmacol; 2019 Dec; 29(2):235-246. PubMed ID: 30552041
[TBL] [Abstract][Full Text] [Related]
55. Effects of Δ9-tetrahydrocannabinol administration on human encoding and recall memory function: a pharmacological FMRI study.
Bossong MG; Jager G; van Hell HH; Zuurman L; Jansma JM; Mehta MA; van Gerven JM; Kahn RS; Ramsey NF
J Cogn Neurosci; 2012 Mar; 24(3):588-99. PubMed ID: 22066583
[TBL] [Abstract][Full Text] [Related]
56. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
57. Inferior frontal and insular cortical thinning is related to dysfunctional brain activation/deactivation during working memory task in schizophrenic patients.
Pujol N; Penadés R; Rametti G; Catalán R; Vidal-Piñeiro D; Palacios E; Bargallo N; Bernardo M; Junqué C
Psychiatry Res; 2013 Nov; 214(2):94-101. PubMed ID: 23993992
[TBL] [Abstract][Full Text] [Related]
58. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Barbier AJ; Hilhorst M; Van Vliet A; Snyder P; Palfreyman MG; Gawryl M; Dgetluck N; Massaro M; Tiessen R; Timmerman W; Hilt DC
Clin Ther; 2015 Feb; 37(2):311-24. PubMed ID: 25438724
[TBL] [Abstract][Full Text] [Related]
59. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.
Girgis RR; Van Snellenberg JX; Glass A; Kegeles LS; Thompson JL; Wall M; Cho RY; Carter CS; Slifstein M; Abi-Dargham A; Lieberman JA
J Psychopharmacol; 2016 May; 30(5):428-35. PubMed ID: 26966119
[TBL] [Abstract][Full Text] [Related]
60. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.
D'Souza DC; Carson RE; Driesen N; Johannesen J; Ranganathan M; Krystal JH;
Biol Psychiatry; 2018 Sep; 84(6):413-421. PubMed ID: 29499855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
